Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.
The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition.
England’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD) instead of more expensive approved drugs
